产品
编 号：F200420
分子式：C1632H2100N610O97P156S4
分子量：50742.05
分子式：C1632H2100N610O97P156S4
分子量：50742.05
产品类型
规格
价格
是否有货
结构图
CAS No: 167362-48-3
产品详情
生物活性：
Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus.
体内研究：
Abetimus (LJP 394 free base) proves effective in suppressing anti-dsDNA-mediated pathologies in male BXSB mice, a model for systemic lupus. Mice dosed with Abetimus (3-300 μg/mouse) i.v. twice weekly, starting around nine weeks of age, has significantly lower titers of anti-dsDNA, lower numbers of anti-dsDNA-secreting spleen cells and less adverse renal histopathology than control mice. Abetimus has a pharmacokinetic half-life ranging from 40 min to 1 h in mice.
体外研究：
Administration of Abetimus (LJP 394 free base) is thought to reduce circulating anti-dsDNA Abs by at least two mechanisms. First, Abetimus (LJP 394 free base) acutely depletes circulating anti-dsDNA antibodies, presumably by forming small, soluble complexes that do not appear to result in significant activation of the complement system. Second, Abetimus (LJP 394 free base) binds B cells without T-cell activation, resulting in their apoptosis and reduced anti-dsDNA antibody production. In fact, Abetimus (LJP 394 free base) appears to induce B-cell tolerance by crosslinking anti-dsDNA surface immunoglobulin receptors on B cells and triggering the signal transduction pathways that lead to B-cell anergy or apoptosis.
Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus.
体内研究：
Abetimus (LJP 394 free base) proves effective in suppressing anti-dsDNA-mediated pathologies in male BXSB mice, a model for systemic lupus. Mice dosed with Abetimus (3-300 μg/mouse) i.v. twice weekly, starting around nine weeks of age, has significantly lower titers of anti-dsDNA, lower numbers of anti-dsDNA-secreting spleen cells and less adverse renal histopathology than control mice. Abetimus has a pharmacokinetic half-life ranging from 40 min to 1 h in mice.
体外研究：
Administration of Abetimus (LJP 394 free base) is thought to reduce circulating anti-dsDNA Abs by at least two mechanisms. First, Abetimus (LJP 394 free base) acutely depletes circulating anti-dsDNA antibodies, presumably by forming small, soluble complexes that do not appear to result in significant activation of the complement system. Second, Abetimus (LJP 394 free base) binds B cells without T-cell activation, resulting in their apoptosis and reduced anti-dsDNA antibody production. In fact, Abetimus (LJP 394 free base) appears to induce B-cell tolerance by crosslinking anti-dsDNA surface immunoglobulin receptors on B cells and triggering the signal transduction pathways that lead to B-cell anergy or apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备